Financial releases

Big improvement in the Gaïa social and environmental rating

Clinical demonstration of ZENEO® efficiency for intramuscular injection of midazolam

First-half 2022 results Achievement of major milestones in the first half On track for a change of dimension

Interest for the ZENEO® auto-injector from an American pharmaceutical company

Safe, fast and effective use of ZENEO® Midazolam validated by a new human factors study in the United States

Great success of the exercise of warrants

ZENEO® Midazolam clinical study: completion of the injection phase

Agreement with BARDA on ZENEO® Midazolam

First injections of ZENEO® Midazolam for the clinical bioequivalence study

2021 annual results - First Marketing Authorization (MA) applications expected to be filed in 2023